Preclinical Testing and Trial Design

The Centre will test lead candidates emerging from the pipeline in our preclinical mouse hospital in the context of ‘standard-of-care’ combination neurosurgery, fractionated irradiation and conventional chemotherapy. The pharmacokinetics, pharmacodynamics and potential biomarkers (tumour, liquid biopsy and imaging) of lead candidates will also be studied.

The groups involved in this stage of the pipeline are: